Clearline Capital LP Acquires 84,283 Shares of QuidelOrtho Corporation $QDEL

Clearline Capital LP lifted its holdings in shares of QuidelOrtho Corporation (NASDAQ:QDEL) by 36.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 316,856 shares of the company’s stock after purchasing an additional 84,283 shares during the period. Clearline Capital LP owned about 0.47% of QuidelOrtho worth $9,049,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Hantz Financial Services Inc. grew its holdings in shares of QuidelOrtho by 50.3% during the 4th quarter. Hantz Financial Services Inc. now owns 1,082 shares of the company’s stock valued at $31,000 after purchasing an additional 362 shares during the last quarter. ProShare Advisors LLC grew its holdings in shares of QuidelOrtho by 3.0% during the 4th quarter. ProShare Advisors LLC now owns 13,164 shares of the company’s stock valued at $376,000 after purchasing an additional 388 shares during the last quarter. State of Alaska Department of Revenue grew its holdings in shares of QuidelOrtho by 1.1% during the 4th quarter. State of Alaska Department of Revenue now owns 38,333 shares of the company’s stock valued at $1,093,000 after purchasing an additional 424 shares during the last quarter. Moody National Bank Trust Division grew its holdings in shares of QuidelOrtho by 1.0% during the 4th quarter. Moody National Bank Trust Division now owns 51,512 shares of the company’s stock valued at $1,471,000 after purchasing an additional 526 shares during the last quarter. Finally, California State Teachers Retirement System grew its holdings in shares of QuidelOrtho by 1.2% during the 2nd quarter. California State Teachers Retirement System now owns 62,188 shares of the company’s stock valued at $1,792,000 after purchasing an additional 725 shares during the last quarter. Institutional investors own 99.00% of the company’s stock.

QuidelOrtho Price Performance

Shares of NASDAQ QDEL opened at $13.13 on Thursday. QuidelOrtho Corporation has a 1 year low of $9.92 and a 1 year high of $35.58. The company has a debt-to-equity ratio of 1.33, a current ratio of 1.43 and a quick ratio of 0.80. The company’s 50-day moving average is $12.86 and its 200 day moving average is $20.96. The stock has a market capitalization of $895.33 million, a P/E ratio of -0.74 and a beta of 0.77.

QuidelOrtho (NASDAQ:QDEL) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.37 by ($0.41). QuidelOrtho had a negative net margin of 45.57% and a positive return on equity of 4.25%. The company had revenue of $619.80 million for the quarter, compared to analysts’ expectations of $665.23 million. During the same quarter in the prior year, the firm earned $0.74 EPS. QuidelOrtho’s quarterly revenue was down 10.5% compared to the same quarter last year. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. On average, sell-side analysts expect that QuidelOrtho Corporation will post 1.83 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on QDEL shares. Citigroup cut their price target on shares of QuidelOrtho from $30.00 to $13.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Weiss Ratings reissued a “sell (e+)” rating on shares of QuidelOrtho in a report on Tuesday, April 21st. Wall Street Zen lowered shares of QuidelOrtho from a “buy” rating to a “hold” rating in a report on Sunday, April 12th. Jefferies Financial Group lowered shares of QuidelOrtho from a “buy” rating to a “hold” rating and cut their price target for the stock from $35.00 to $12.50 in a report on Thursday, May 7th. Finally, UBS Group reissued a “neutral” rating and issued a $12.00 price target on shares of QuidelOrtho in a report on Thursday, May 7th. Four analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, QuidelOrtho presently has a consensus rating of “Reduce” and a consensus target price of $14.88.

QuidelOrtho Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.